Related references
Note: Only part of the references are listed.HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi et al.
CLINICAL CANCER RESEARCH (2011)
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma
David Siegel et al.
LEUKEMIA & LYMPHOMA (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Geldanamycin selectively targets the nascent form of ERBB3 for degradation
Candice S. Gerbin et al.
CELL STRESS & CHAPERONES (2010)
The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas
Jeremy S. Abramson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib
Ching Ching Leow et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Dongweon Song et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Heat shock protein 90 - A potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors
Cong Peng et al.
CELL CYCLE (2007)
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
R Bruno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel
B Leyland-Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
AD Basso et al.
ONCOGENE (2002)
Share Paper
